

Dr. Rick Kuntz appointed as consulting Chief Scientific Officer

Sunnyvale, California; 22 February 2023: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing system for heart failure, is pleased to announce that it has appointed Dr. Rick Kuntz as consulting Chief Scientific Officer.

Dr. Kuntz has a broad background and expertise in many different areas of healthcare. He previously served as Senior Vice President, Chief Medical and Scientific Officer of Medtronic overseeing medical affairs, health policy, reimbursement, clinical research activities and corporate technology. In addition, he was the Founder and Chief Scientific Officer of the Harvard Research Institute (HCRI), a university-based contract research organisation which coordinates National Institutes of Health (NIH) and clinical trials with the United States Food and Drug Administration (FDA).

Over his career, Dr. Kuntz has directed numerous multicentre clinical trials and has authored more than 250 original publications. He graduated from Miami University and received his medical degree from Case Western Reserve University School of Medicine. He also completed fellowships in cardiovascular diseases and interventional cardiology at the Beth Israel Hospital and Harvard Medical School. He has received his Master of Science and Biostatistics from the Harvard School of Public Health.

Allan Will, Chairman of EBR Systems said:

“We are extremely delighted to have Rick on board as our consulting Chief Scientific Officer. His experience overseeing clinical trials, particularly within the cardiac rhythm management space is unparalleled. Rick will provide invaluable advice and counsel as we progress through the final stages of our pivotal SOLVE-CRT trial and regulatory activities.”

Dr. Rick Kuntz said:

“EBR Systems is a clear leader in innovation within the cardiac rhythm management space and it has a device that can potentially takeover conventional methods as the first-in-line pacing device for heart failure patients. I look forward to helping further the Company’s goals and am excited to work with a passionate team dedicated to improving the lives of many patients.”

ENDS

This announcement has been authorised for release by John McCutcheon, President and CEO.

For more information, please contact:

Company

Frank Hettmann
Chief Financial Officer
P: +1 408 720 1906
E: info@ebrsystemsinc.com

Investors

Dean Dribbin
Vesparum Capital
P: +61 3 8582 4800
E: EBRSystems@vesparum.com

About EBR Systems (ASX: EBR)

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR Systems' WiSE® Technology

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the US.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Given the current uncertainties regarding the impact of the COVID-19 on the trading conditions impacting the Company, the financial markets and the health services world-wide, investors are cautioned not to place undue reliance on the current trading outlook.

EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.